97 related articles for article (PubMed ID: 30590392)
1. Antiangiogenic effects of the chemopreventive agent tributyrin, a butyric acid prodrug, during the promotion phase of hepatocarcinogenesis.
Andrade FO; Furtado KS; Heidor R; Sandri S; Hebeda CB; Miranda MLP; Fernandes LHG; Yamamoto RC; Horst MA; Farsky SHP; Moreno FS
Carcinogenesis; 2019 Aug; 40(8):979-988. PubMed ID: 30590392
[TBL] [Abstract][Full Text] [Related]
2. The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway.
de Conti A; Tryndyak V; Koturbash I; Heidor R; Kuroiwa-Trzmielina J; Ong TP; Beland FA; Moreno FS; Pogribny IP
Carcinogenesis; 2013 Aug; 34(8):1900-6. PubMed ID: 23568954
[TBL] [Abstract][Full Text] [Related]
3. Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein.
Ortega JF; de Conti A; Tryndyak V; Furtado KS; Heidor R; Horst MA; Fernandes LH; Tavares PE; Pogribna M; Shpyleva S; Beland FA; Pogribny IP; Moreno FS
Oncotarget; 2016 Apr; 7(17):24339-47. PubMed ID: 27013579
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic responses provide a new mechanistic basis for the chemopreventive effects of folic acid and tributyrin in rat liver carcinogenesis.
Guariento AH; Furtado KS; de Conti A; Campos A; Purgatto E; Carrilho J; Shinohara EM; Tryndyak V; Han T; Fuscoe JC; Ross SA; Beland FA; Pogribny IP; Moreno FS
Int J Cancer; 2014 Jul; 135(1):7-18. PubMed ID: 24302446
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug.
Kuroiwa-Trzmielina J; de Conti A; Scolastici C; Pereira D; Horst MA; Purgatto E; Ong TP; Moreno FS
Int J Cancer; 2009 Jun; 124(11):2520-7. PubMed ID: 19195022
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling.
Liu P; Atkinson SJ; Akbareian SE; Zhou Z; Munsterberg A; Robinson SD; Bao Y
Sci Rep; 2017 Oct; 7(1):12651. PubMed ID: 28978924
[TBL] [Abstract][Full Text] [Related]
7. Chemopreventive effects of the dietary histone deacetylase inhibitor tributyrin alone or in combination with vitamin A during the promotion phase of rat hepatocarcinogenesis.
de Conti A; Kuroiwa-Trzmielina J; Horst MA; Bassoli BK; Chagas CE; Purgatto E; Cavalher FP; Camargo AA; Jordão AA; Vannucchi H; Scolastici C; Ong TP; Moreno FS
J Nutr Biochem; 2012 Aug; 23(8):860-6. PubMed ID: 21940155
[TBL] [Abstract][Full Text] [Related]
8. The chemopreventive activity of butyrate-containing structured lipids in experimental rat hepatocarcinogenesis.
Heidor R; de Conti A; Ortega JF; Furtado KS; Silva RC; Tavares PE; Purgatto E; Ract JN; de Paiva SA; Gioielli LA; Pogribny IP; Moreno FS
Mol Nutr Food Res; 2016 Feb; 60(2):420-9. PubMed ID: 26548572
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis.
Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma.
Pan L; Xiao H; Liao R; Chen Q; Peng C; Zhang Y; Mu T; Wu Z
Biomed Pharmacother; 2018 Oct; 106():68-76. PubMed ID: 29957468
[TBL] [Abstract][Full Text] [Related]
13. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic activity of vitexicarpine in experimentally induced hepatocellular carcinoma: Impact on vascular endothelial growth factor pathway.
Hassoun SM; Abdel-Rahman N; Eladl EI; El-Shishtawy MM
Tumour Biol; 2017 Jun; 39(6):1010428317707376. PubMed ID: 28651490
[TBL] [Abstract][Full Text] [Related]
15. The chemopreventive activity of the histone deacetylase inhibitor tributyrin in colon carcinogenesis involves the induction of apoptosis and reduction of DNA damage.
Heidor R; Furtado KS; Ortega JF; de Oliveira TF; Tavares PE; Vieira A; Miranda ML; Purgatto E; Moreno FS
Toxicol Appl Pharmacol; 2014 Apr; 276(2):129-35. PubMed ID: 24576724
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1/2/HIF-1α/VEGFA signalling in hepatocellular carcinoma.
Lin J; Cao S; Wang Y; Hu Y; Liu H; Li J; Chen J; Li P; Liu J; Wang Q; Zheng L
J Exp Clin Cancer Res; 2018 Jun; 37(1):113. PubMed ID: 29866133
[TBL] [Abstract][Full Text] [Related]
17. Expression and correlation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis.
Wang W; Xu GL; Jia WD; Wang ZH; Li JS; Ma JL; Ge YS; Xie SX; Yu JH
J Int Med Res; 2009; 37(2):417-25. PubMed ID: 19383236
[TBL] [Abstract][Full Text] [Related]
18. β-ionone modulates the expression of miRNAs and genes involved in the metastatic phenotype of microdissected persistent preneoplastic lesions in rats submitted to hepatocarcinogenesis.
Furtado KS; de Oliveira Andrade F; Campos A; Rosim MP; Vargas-Mendez E; Henriques A; De Conti A; Scolastici C; Barbisan LF; Carvalho RF; Moreno FS
Mol Carcinog; 2017 Jan; 56(1):184-196. PubMed ID: 27061051
[TBL] [Abstract][Full Text] [Related]
19. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
Yeo EJ; Chun YS; Cho YS; Kim J; Lee JC; Kim MS; Park JW
J Natl Cancer Inst; 2003 Apr; 95(7):516-25. PubMed ID: 12671019
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of hepatic hypoxia-inducible factor-1alpha and its abnormal gene expression during the formation of hepatocellular carcinoma.
Yao DF; Jiang H; Yao M; Li YM; Gu WJ; Shen YC; Qiu LW; Wu W; Wu XH; Sai WL
Hepatobiliary Pancreat Dis Int; 2009 Aug; 8(4):407-13. PubMed ID: 19666411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
